FLUOKSETİN VE TRAZODON KULLANIRKEN TEK BİR DOZ KETİYAPİN EKLENMESİYLE GELİŞEN BİR AKUT DİSTONİ OLGUSU

A patient admitted with complaints of muscle contractions in neck, shoulder and arm which started recently after quetiapine administration. As a result the patient developed dystonia after adding a single dose of 12.5 mg/day quetiapine while taking trazodone and fluoxetine treatment. In this paper we take a look at the literature concerning quetiapine and dystonia. In this context it is warranted to be aware of combination therapy’s side effects, including ones that are considered having a lower risk of extrapyramidal symptoms such as quetiapine

Total white blood cell count, liver enzymes, and metabolic syndrome in schizophrenia

Background/aim: Metabolic syndrome (MetS) is an important clinical issue in patients with schizophrenia, but its associated factors are still ambiguous. The aim of the present study was to test whether there are any associations between MetS and white blood cell (WBC) levels, liver enzymes, or sociodemographic variables. Materials and methods: The study included 91 patients with a diagnosis of schizophrenia. We used the National Cholesterol Education Program’s Third Adult Treatment Protocol criteria to evaluate MetS in patients. Schizophrenia patients with MetS were compared with those without MetS on the basis of demographic and clinical characteristics and total WBC counts. We conducted Spearman’s correlation and binary logistic regression analyses to achieve the best prediction of MetS in schizophrenia. Results: Compared with schizophrenia patients without MetS, those with MetS were older, less educated, and more likely to be smokers. They were also more likely to have a longer duration of the illness, a longer untreated period, and higher alanine aminotransferase (ALT) and WBC levels. MetS was correlated with age, duration of illness, income, ALT, gamma-glutamyl transpeptidase, WBC, and hemoglobin values. Age and WBC levels were found to be the best predictors of MetS. Conclusion: Hemograms and liver tests should be conducted to test for MetS in schizophrenia.Background/aim: Metabolic syndrome (MetS) is an important clinical issue in patients with schizophrenia, but its associated factors are still ambiguous. The aim of the present study was to test whether there are any associations between MetS and white blood cell (WBC) levels, liver enzymes, or sociodemographic variables. Materials and methods: The study included 91 patients with a diagnosis of schizophrenia. We used the National Cholesterol Education Program’s Third Adult Treatment Protocol criteria to evaluate MetS in patients. Schizophrenia patients with MetS were compared with those without MetS on the basis of demographic and clinical characteristics and total WBC counts. We conducted Spearman’s correlation and binary logistic regression analyses to achieve the best prediction of MetS in schizophrenia. Results: Compared with schizophrenia patients without MetS, those with MetS were older, less educated, and more likely to be smokers. They were also more likely to have a longer duration of the illness, a longer untreated period, and higher alanine aminotransferase (ALT) and WBC levels. MetS was correlated with age, duration of illness, income, ALT, gamma-glutamyl transpeptidase, WBC, and hemoglobin values. Age and WBC levels were found to be the best predictors of MetS. Conclusion: Hemograms and liver tests should be conducted to test for MetS in schizophrenia

Extended-release trazodone in the treatment of major depressive disorder

Majör depresif bozukluk (MDB) sık görülen bir psikiyatrik bozukluktur. Tedavinin amacı belirtilerde remisyon ile günlük işlevlerin düzelmesidir ve antidepresanlar, majör depresif bir nöbetin (orta-şiddetli depresif nöbet) ilk sırada gelen tedavileridir. Bu makale uzatılmış salımlı trazodonun (TzCOAD) farmakolojik özelliklerini, MDB’deki klinik etkinliği ve güvenliğini incelemektedir. Uzman görüşü: Günde tek doz TzCOAD, hızlı salımlı trazodon (TzIR) ve diğer antidepresanlara benzer bir etkinlik ve artmış tolerabilite sağlayabilir. (Anadolu Psikiyatri Derg 2019; 20(5):453-459)Major depressive disorder is a common psychiatric disorder. the aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). in this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants. (Anatolian Journal of Psychiatry 2019; 20(5):453-459

Kanser hastalarında yaşam kalitesinin iyileştirilmesi ve uyku bozukluklarının tedavisinde uyku hijyeni ve psikopatolojinin yeri: Bir yol analizi çalışması

Amaç: Kanser hastalarında uyku bozuklukları, uyku hijyeni, psikopatoloji ve yaşam kalitesi kavramlarını bütüncül bir çerçevede ele alan az sayıda çalışma vardır. Özellikle uyku hijyeni erişkin kanser hastalarında uyku bozukluklarının tedavisinde yer almasına rağmen etkinliğine dair çalışma yoktur. Çalışmanın amacı bu kavramlar arasındaki ilişkilerin yön ve büyüklüklerini modellemek ve böylece klinik pratiğe katkı sunmaktır. Yöntem: Bu çalışma kanser tanısı almış 34 katılımcı ve 16 sağlıklı kontrolden oluşan iki grup üzerinde yapılmıştır. Katılımcılar uyku hijyeni ve bozuklukları, psikopatoloji ve yaşam kalitesi bakımından karşılaştırılmıştır. Bulgular: Kanser hastalarında uyku hijyeni, uyku sağlığı, ruh sağlığı ve yaşam kalitesi kontrol grubuna göre anlamlı düzeyde bozulmuştur. Ancak uyku hijyeninde bozulmanın uyku bozuklukları, psikopatoloji ve yaşam kalitesi üzerinde etkisi saptanmamıştır. Uyku bozuklukları psikopatolojideki artışa ikincil olarak geliştiği saptanmıştır. Sonuç: Kanser hastalarında uyku bozukluklarının tedavisinde uyku hijyeni önerileri hastaya göre ve dikkatli seçilmeli ve etkileri sınırlı olabileceği için bu hastalarda uyku bozukluklarındaki gidişin yakın izlenmesi gereklidir. Ayrıca kanser hastalarında uyku bozuklukları ve yaşam kalitesinin iyileştirilmesinde temel hedefin hastadaki psikopatoloji düzeyi olması gerektiği sonucuna ulaşılmıştır